AZTA vs DGX: fair value comparison
Azenta, Inc. and Quest Diagnostics Incorporated · Updated 2026-10-19
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, DGX currently sits closer to the top of our ranking by discount to fair value. DGX carries the stronger quality grade.
| AZTA | DGX | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $34.09 | $230.97 |
| 12-month range | $16.02–$42.73 | $173.49–$247.45 |
| Rank by discount to fair value | #107 of 108 Healthcare | #82 of 108 Healthcare |
| Quality grade | D | B |
| Leverage | Low | Moderate |
| Margin trend | Contracting | Stable |
| Revenue growth | Declining | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | — |
| DCF cross-check | — | Overvalued |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: AZTA fair value analysis · DGX fair value analysis